An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus (RSV) for ...

The new research, published Monday (Dec. 9) in the journal JAMA Pediatrics, focused on nirsevimab (Beyfortus), a drug approved in 2023. The medicine, which is given as an injection, uses lab-made ...

Immunisation with nirsevimab reduced bronchiolitis-related hospitalisations among infants younger than 3 months who visited the emergency department (ED), according to a new study. Nirsevimab also ...

Nirsevimab-resistant respiratory syncytial virus variants remain rare, but continued molecular surveillance is crucial. Read now.

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

The Allan Labor Government is keeping Victorian babies safe from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation ...

Sanofi bought into the nirsevimab programme in 2017, paying $645 million for marketing rights to the antibody, with AZ retaining the responsibility for developing and manufacturing it.

Fresno County confirmed the first pediatric influenza and respiratory syncytial virus (RSV) death on Tuesday. By the numbers: ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

Visit the CoMMinS study website for full details and results. Title: A Phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory ...